Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells

Free Radical Biology and Medicine

Volumn 20, Issue 7, 1996, Pages 905-914

  Malisza, Krisztina L ^a   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anthracycline; Cell; Dexrazoxane; Doxorubicin; EPR; Fre e radicals; ICRF 187; Idarubicin; Semiquinone

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FREE RADICAL; IDARUBICIN; RAZOXANE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEMIQUINONE;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CELL METABOLISM; CELL SUSPENSION; CELL TRANSPORT; CHO CELL; DRUG INHIBITION; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; HYPOXIC CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0029892535     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/0891-5849(95)02188-4     Document Type: Article

References (47)

1. Gianni, L.; Corden, B. J.; Myers, C. E. The biochemical basis of anthracycline toxicity and anti-tumor activity. Rev. Biochem. Toxicol. 5:1-82; 1983.
2. Weiss, R. B. The anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 19:670-686; 1992.
3. Gutteridge, J. M. C. Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron(III) complex. Biochem. Pharmacol. 33:1725-1728; 1984.
4. Gianni, L.; Zweier, J. L.; Levy, A.; Myers, C. E. Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J. Biol. Chem. 260:6820-6826; 1985.
5. Halliwell, B,; Gutteridge, J. M. C. Free radicals in biology and medicine. 2nd ed. Oxford: Clarendon; 1989.
6. Bachur, N. R.; Gordon, S. L.; Gee, M. V.; Kon, H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. USA 76:954-957; 1979.
7. Sato, S.; Iwaizumi, M.; Hanada, K.; Tamura, Y. Electron spin resonance study on the mode of generation of free radicals of daunomycin, adriamycin, and carboquone in NAD(P)H-microsome system. Gann 68:603-608; 1977.
8. Kalyanaraman, B.; Perez-Reyes, E.; Mason, R. P. Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim. Biophys. Acta 630:119-130; 1980.
9. Hoey, B. M.; Butler, J.; Lea, J. S.; Sarna, T. A comparison of the free radical properties of several anthracycline anti-tumour drugs and some of their analogues. Free Radic. Res. Commun. 5:169-176; 1988.
10. 2 reduction by the iron complexes of adriamycin and daunomycin: The importance of the sidechain hydroxyl group. Biochim. Biophys. Acta 884:326-336; 1986.
11. 3+-doxorubicin complex undergoing self-reduction by its α-ketol group. Biochem. Cell Biol. 68:1331-1336; 1990.
12. Speyer, J. L.; Green, M. D.; Zeleniuch-Jacquotte, A.; Wernz, J. C.; Rey, M.; Sanger, J.; Kramer, E.; Ferrans, V.; Hochster, H.; Meyers, M.; Blum, R. H.; Feit, F.; Attubato, M.; Burrows, W.; Muggia, F. M. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Clin. Oncol. 10:117-127; 1992.
13. Hasinoff, B. B. The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis (3,5-dioxopiperazinyl-1-yl)propane), its hydrolysis product ICRF-198, and other chelating agents with the Fe(III) and Cu(II ) complexes of adriamycin. Agents Actions 26:378-385; 1989.
14. Hasinoff, B. B. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis (3,5-dioxopiperazinyl-1-yl )propane). Agents Actions 29:374-381; 1990.
15. Huang, Z.-X.; May, P. M.; Quinlan, K. M.; Williams, D. R.; Creighton, A. M. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 12:536-542; 1982.
16. Buss, J. L.; Hasinoff, B. B. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40:86-95; 1993.
17. Dawson, K. M. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem. Pharmacol. 24:2249-2253; 1975.
18. Hasinoff, B. B. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane). Free Radic. Res. 22:319-325; 1995.
19. Malisza, K. L.; Hasinoff, B. B. Doxorubicin reduces the iron (III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals. Arch. Biochem. Biophys. 316:680-688; 1995.
20. Von Hoff, D. D.; Lazard, M. W.; Basa, P.; Davis, H. L.; Von Hoff, A. L.; Rozencweig, M.; Muggia, F. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91:710-717; 1979.
21. Von Hoff, D. D.; Rozencweig, M.; Layard, M.; Slavik, M.; Muggia, F, M, Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med. 62:200-210; 1977.
22. Burke, T. G.; Pritos, C. A.; Sartorelli, A. C.; Tritton, T. R. The structural basis for anthracycline antibiotic stimulation of oxygen consumption by HL-60 cells and mitochondria. Cancer Biochem. Biophys. 9:245-255; 1987.
23. Budavari, S., ed. The Merck index. 11th ed. Rahway: Merck & Co.; 1989.
24. Swartz, H. M.; Bolton, J. R.; Borg, D, C. Biological applications of electron spin resonance. Toronto: John Wiley & Son; 1972:100.
25. Tarasiuk, A.; Garnier-Suillerot, A. Thermodynamics of the anthracycline-nuclei interactions in drug-resistant and drug-sensitive K562 cells. Biochem. Pharmacol. 43:2575-2580; 1992.
26. Kalyanaraman, B.; Morehouse, K. M.; Mason, R. P. An electron paramagnetic resonance study of the interactions between the adriamycin semiquinone, hydrogen peroxide, iron-chelators, and radical scavengers. Arch. Biochem. Biophys. 286:164-171; 1991.
27. Alegria, A. F.; Samuni, A.; Mitchell, J. B.; Riesz, P.; Russo, A. Free radicals induced by adriamycin-sensitive and adriamycin-resistant cells: A spin trapping study. Biochemistry 28:8653-8658; 1989.
28. Fisher, G. R.; Gutierrez, P. L.; Oldcorne, M. A.; Patterson, L. H. NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase)-mediated two-electron reduction of anthraquinone-based antitumor agents and generation of hydroxyl radicals. Biochem. Pharmacol. 43:575-585; 1992.
29. Hasinoff, B. B. An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int. J. Pharmaceut. 107:67-76; 1994.
30. Hasinoff, B. B. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane)). J. Pharm. Sci. 83:64-67; 1994.
31. Skovsgaard, T.; Nissen, N. I. Membrane transport of anthracyclines. Pharmacol. Ther. 18:293-311; 1982.
32. Grandi, M.; Giuliani, F. C.; Verhoef, V.; Filippi, J. Screening of anthracycline analogs. In: Lown, J. W., ed. Anthracycline and anthracenedione-based anticancer agents. Vol. 6. Amsterdam: Elsevier; 1988:571-597.
33. Berman, E.; McBride, M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug resistant leukemia cells. Blood 79:3267-3272; 1992.
34. Davies, K. J. A.; Doroshow, J. H. Redox cycling of anthracyclines by cardiac mitrochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261:3060-3067; 1986.
35. Myers. C. E.; Mimnaugh, E. G.; Yeh, G. C.; Sinha, B. K. Biochemical mechanisms of tumor cell kill by the anthracyclines, In: Lown, J. W., ed. Anthracycline and anthracenedione-based anticancer agents. Vol. 6. Amsterdam: Elsevier; 1988:527-569.
36. Goormaghtigh, E.; Huart, P.; Praet, M.; Brasseur, R.; Ruysschaert, J.-M. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys. Chem. 35:247-257; 1990.
37. Constantinides, P. P.; Wang, Y. Y.; Burke, T. G.; Tritton, T. R. Transverse location of anthracyclines in lipid bilayers. Paramagnetic quenching studies. Biophys. Chem. 35:259-264; 1990.
38. Crane, F. L.; Sun, I. L.; Clark, M. G.; Grebing, C.; Low, H. Transplasma-membrane redox systems in growth and development. Biochim. Biophys. Acta 811:233-264; 1985.
39. Alegria, A. E,; Rodriguez, M. S.; Hernandez, J. Semiquinones derived from anthraquinone-containing antitumor drugs can partition into phosphatidylcholine bilayers. Biochim. Biophys. Acta 1035:51-55; 1990.
40. Friche, E.; Jensen, P. B.; Roed, H.; Skovsgaard, T.; Nissen, N. I. In vitro circumvention of anthracycline-resistance in ehrlich ascites tumor by anthracycline analogues. Biochem. Pharmacol. 39:1721-1726; 1990.
41. Dorr, R. T.; Shipp, N. G.; Lee, K. M. Comparison of cytoxicity in heart cells and tumor cells exposed to to DNA intercalating agents in vitro. Anti-Cancer Drugs 2:27-33; 1991.
42. Vile, G. F.; Winterbourn, C. C. Microsomal lipid peroxidation induced by Adriamycin, epirubicin, daunorubicin and mitoxantrone: A comparative study. Cancer Chemother. Pharmacol. 24:105-108; 1989.
43. Yeung, T. K.; Simmonds, R. H.; Hopewell, J. W. A functional assessment of the relative cardiotoxicity of adriamycin and epirubicin in the rat. Radiother. Oncol. 15:275-284; 1989.
44. Le Bot, M. A.; Begue, J. M.; Kernaleguen, D.; Robert, J.; Ratanasavanh, D.; Airiau, J.; Riche, C.; Guillouzo, A. Different cytoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochem. Pharmacol. 37:3877-3887; 1988.
45. Tanabe, K.; Ikegami, Y.; lshida, R.; Andoh, T. Inhibition of topoisomerase II by antitumor agents bis (2,6-dioxopiperazine) derivatives. Cancer Res. 51:4903-4908; 1991.
46. Hasinoff, B. B. The enzymatic ring-opening reactions of the chiral cardioprotective agent (+)(S)-ICRF-187 and its (-)(R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab. Dispos. 21:883-888; 1993.
47. Hochster, H.; Liebes, L.; Wadler, S.; Oratz, R.; Wernz, J. C.; Meyers, M.; Green, M.; Blum, R. H.; Speyer, J. L. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst. 84:1725-1730; 1992.